Telix Pharmaceuticals Limited
HealthcareNASDAQ:TLX · NASDAQ Global Select
+$0.11 today
Vol 0.38M · Avg 0.21M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-1.7%
avg -362.4%
ROIC
1.8%
avg -21.6%
ROA
-0.6%
avg -17.8%
Analysis
ROIC is currently the strongest return metric at 1.8% versus its period average of -21.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Christian Behrenbruch GAICD | Co-Founder, MD, Group Chief Executive Officer & Executive Director | $692,001.00 | — | 50 | $20.74M | 6.12% |
Darren Smith FCPA | Group Chief Financial Officer | $636,308.00 | — | 61 | $11,921.00 | <0.01% |
Darren Patti | Group Chief Operating Officer | $494,412.00 | — | 53 | $11,921.00 | <0.01% |
David N. Cade MBBS | Group Chief Medical Officer | $474,096.00 | — | 56 | $0.00 | <0.01% |
Christian Krautkramer | Group General Counsel | — | — | — | $20.74M | 6.12% |
Craig Ulrick | Chief Information Officer | — | — | — | — | — |
Meredith Crowe BDES | Senior Vice President of Global People & Culture | — | — | — | — | — |
Thomas Fromm | Vice President of Sales | — | — | — | — | — |
Kyahn Williamson | Senior Vice President of Corporate Communications & Investor Relations | — | — | — | — | — |
Paul Schaffer | SVP of Research & Development | — | — | — | $2,500.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$996,738.45
Sells
0
$0.00
Net Sentiment
+$996,738.45
Net buying
Most Active
Behrenbruch Christian
2 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Apr 29, 2026 | Behrenbruch Christian Indirect | Buy | 33.4K | $14.87 | $497,178.45 | |
| Apr 28, 2026 | Behrenbruch Christian Indirect | Buy | 34.5K | $14.48 | $499,560.00 |
Analysis
Insiders reported 2 buys worth $996,738.45 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $996,738.45. Behrenbruch Christian was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$5.64B
Belite Bio, Inc
NASDAQ:BLTE
$5.54B
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
$5.12B
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
$4.99B
Celcuity Inc.
NASDAQ:CELC
$4.32B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.61B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.01B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.40B
ADMA Biologics, Inc.
NASDAQ:ADMA
$1.90B
Who manages TLX?
Telix Pharmaceuticals Limited (TLX) lists 10 active executives. The top listed executive is Christian Krautkramer, Group General Counsel.
Are TLX insiders buying or selling?
Recent insider activity shows net buying of $1.03M.
Explore More
Continue the stock analysis
Jump to another research area for this company.